rpid-20240503

0001380106-24-000125.txt : 20240503 0001380106-24-000125.hdr.sgml : 20240503 20240503070353 ACCESSION NUMBER: 0001380106-24-000125 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20240503 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240503 DATE AS OF CHANGE: 20240503 FILER: COMPANY DATA: COMPANY CONFORMED NAME: RAPID MICRO BIOSYSTEMS, INC. CENTRAL INDEX KEY: 0001380106 STANDARD INDUSTRIAL CLASSIFICATION: LABORATORY ANALYTICAL INSTRUMENTS [3826] ORGANIZATION NAME: 08 Industrial Applications and Services IRS NUMBER: 000000000 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40592 FILM NUMBER: 24910764 BUSINESS ADDRESS: STREET 1: 1001 PAWTUCKET BLVD. CITY: LOWELL STATE: MA ZIP: 01854 BUSINESS PHONE: 978-349-3200 MAIL ADDRESS: STREET 1: 1001 PAWTUCKET BLVD. CITY: LOWELL STATE: MA ZIP: 01854 FORMER COMPANY: FORMER CONFORMED NAME: RAPID MICRO BIOSYSTEMS INC DATE OF NAME CHANGE: 20061103 8-K 1 rpid-20240503.htm 8-K rpid-20240503

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of report (Date of earliest event reported): May 3, 2024

RAPID MICRO BIOSYSTEMS, INC.

(Exact name of registrant as specified in its charter)


Delaware	001-40592	20-8121647
(State or other jurisdiction of incorporation or organization)	(Commission File Number)	(I.R.S. Employer Identification No.)
1001 Pawtucket Boulevard West, Suite 280, Lowell, MA		01854
(Address of principal executive offices)		(Zip Code)

978-349-3200

(Registrant’s telephone number, including area code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


o			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading
Symbols

Name of each exchange on which
registered

Class A Common Stock, $0.01 par value per share

RPID

The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company þ

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. o

Item 2.02 Results of Operations and Financial Condition.

On May 3, 2024, Rapid Micro Biosystems, Inc. (the “Company”) issued a press release announcing its unaudited financial results for its first quarter ended March 31, 2024. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference in its entirety.

The information furnished under this Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended (the "Securities Act"), or the Exchange Act, except as otherwise expressly stated in such filing.

Item 9.01 Financial Statements and Exhibits.

(d)Exhibits.


Exhibit No.						Description
99.1						Press Release of Rapid Micro Biosystems, Inc. dated May 3, 2024
104						Cover Page Interactive Data File (formatted as inline XBRL)

Cautionary Statement Regarding Forward-Looking Statements

This Current Report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this Current Report on Form 8-K that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance for full year 2024 revenue, system placements and gross margins; financial position and cash runway; expected placements of Growth Direct systems, anticipated timing of such placements and the impact on the Company’s revenue; intentions regarding the Company's commercial execution and improvements to gross margins; and the upcoming launch of Growth Direct Rapid Sterility and the timing thereof.

In some cases, you can identify forward-looking statements by terminology such as “outlook,” “aim,” “anticipate,” “assume,” “believe,” “contemplate,” “continue,” “could,” “due,” “estimate,” “expect,” “goal,” “intend,” “may,” “objective,” “plan,” “predict,” “potential,” “positioned,” “seek,” “should,” “target,” “will,” “would” and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or other comparable terminology, although not all forward-looking statements contain these words. Forward-looking statements involve known and unknown risks, uncertainties and assumptions which may cause actual results to differ materially from any results expressed or implied by any forward-looking statement, including, but not limited to, the Company’s significant losses since inception; the Company’s ability to meet its publicly announced guidance and other expectations about its business and operations; the Company’s limited experience in marketing and sales and the effectiveness of its sales processes; the Company’s need to develop new products and adapt to technological changes; the Company’s ability to establish and maintain its position as a leading provider of automated microbial quality control testing; the Company’s ability to maintain its manufacturing facility; the Company's ability to improve the gross margins of its products and services; risks related to third-parties; the Company’s ability to retain key management and other employees; risks related to regulatory and intellectual property matters; risks related to supply chain disruptions and the impact of inflation; the impact of macroeconomic volatility; and the other important factors outlined under the caption “Risk Factors” in the Company’s Annual Report on Form 10-K filed with the Securities and Exchange Commission (“SEC”) on March 1, 2024, as such factors may be updated from time to time in its other filings with the SEC, which are available on the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this Current Report on Form 8-K to reflect changes since the date of this Current Report on Form 8-K, except as may be required by law.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


	RAPID MICRO BIOSYSTEMS, INC.

Date: May 3, 2024	By:	/s/ Sean Wirtjes
		Sean Wirtjes
		Chief Financial Officer

EX-99.1 2 rpid-20240503xexx991x20240.htm EX-99.1 Document

Exhibit 99.1

Rapid Micro Biosystems Reports First Quarter 2024 Financial Results

Reports first quarter 2024 total revenue of $5.6 million, representing growth of 11% compared to first quarter 2023

Reaffirms full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023

LOWELL, Mass., May 3, 2024 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced its financial results for the first quarter ended March 31, 2024.

Recent Highlights

•First quarter total revenue (combined product and service revenue) increased 11% to $5.6 million

•First quarter recurring revenue increased 15% to $3.7 million, including record consumable revenue

•Placed three Growth Direct systems and completed the validation of three customer systems

•Growth Direct Rapid Sterility platform on track for mid-2024 launch

"We are pleased to report a solid start to 2024," said Robert Spignesi, President and CEO. "First quarter revenues exceeded our guidance and we achieved a new record in consumable revenue in the period. We remain focused on accelerating Growth Direct® system placements, improving gross margins and driving the business to profitability. We are reaffirming our full year 2024 total revenue guidance as we look forward to the mid-year launch of our innovative Growth Direct Rapid Sterility platform."

First Quarter Financial Results

Total revenue for the first quarter of 2024 increased 11% to $5.6 million compared to $5.0 million in the first quarter of 2023. The Company placed three new Growth Direct® systems and completed the validation of three customer systems compared to three placements and two validations in the first quarter of 2023. Product revenue increased primarily due to higher consumable revenue. Service revenue increased due to increased validation activities as well as higher revenue from service contracts due to an increase in the number of validated Growth Direct systems. Recurring revenue increased 15% to $3.7 million, compared to $3.3 million in the first quarter last year, due to the growth in both consumables and service contracts.

Total cost of revenue was $7.1 million in the first quarter of 2024, compared to $6.8 million in the first quarter of 2023, representing an increase of 5%. The increase was primarily due to higher product costs associated with increased consumable volumes and higher service costs to support the larger number of validated systems at customer sites.

Total operating expenses were $12.8 million in the first quarter of 2024, compared to $13.1 million in the first quarter of 2023. The decrease was largely due to nonrecurring retention costs incurred in the first quarter last year, partially offset by an increase in costs associated with the planned upcoming launch of Growth Direct Rapid Sterility.

Net loss for the first quarter of 2024 was $13.3 million, compared to $13.9 million in the first quarter of 2023. The improvement was due to higher revenue, improved gross margins and lower operating expenses. Net loss per share for the first quarter of 2024 was $0.31, compared to $0.32 in the first quarter of 2023.

Cash, cash equivalents and investments were $79.5 million as of March 31, 2024, which the Company continues to expect to provide a cash runway at least into the second half of 2026. The Company had no debt outstanding as of March 31, 2024.

2024 Outlook

The Company is reaffirming its full year 2024 total revenue guidance of at least $27.0 million, representing growth of at least 20% compared to full year 2023, and the placement of at least 20 systems. The Company continues to expect gross margin to be positive for the full year 2024.

Webcast Details

The Company will host a conference call before the market opens today, May 3, 2024, at 8:30 a.m. ET to discuss its first quarter 2024 financial results. The live call is accessible on the Company’s website at investors.rapidmicrobio.com and will be archived and available for replay for one year.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Lexington, Massachusetts, Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly know as Twitter) at @rapidmicrobio or on LinkedIn.

Forward-Looking Statements

This press release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including, but not limited to, statements regarding the Company’s guidance for full year 2024 revenue, system placements and gross margins; financial position and cash runway; expected placements of Growth Direct systems, anticipated timing of such placements and the impact on the Company’s revenue; intentions regarding the Company’s commercial execution and improvements to gross margins; and the upcoming launch of Growth Direct Rapid Sterility and the timing thereof.

the SEC's website at www.sec.gov and the Investor Relations page of its website at investors.rapidmicrobio.com. Although the Company believes that the expectations reflected in its forward-looking statements are reasonable, it cannot guarantee future results. The Company has no obligation, and does not undertake any obligation, to update or revise any forward-looking statement made in this press release to reflect changes since the date of this press release, except as may be required by law.

Investor Contact

Michael Beaulieu, CFA

Vice President, Investor Relations and Corporate Communications

investors@rapidmicrobio.com

Media Contact

media@rapidmicrobio.com

RAPID MICRO BIOSYSTEMS, INC.

Unaudited Condensed Consolidated Statements of Operations

(in thousands, except share and per share amounts)


	Three Months Ended March 31,
	2024		2023
Revenue:
Product revenue	$	3,713	$	3,324
Service revenue	1,898		1,711
Total revenue	5,611		5,035
Costs and operating expenses:
Cost of product revenue	5,173		4,981
Cost of service revenue	1,961		1,844
Research and development	3,842		3,153
Sales and marketing	3,281		3,462
General and administrative	5,627		6,467
Total costs and operating expenses	19,884		19,907
Loss from operations	(14,273)		(14,872)
Other income (expense):
Interest income, net	983		1,003
Other expense, net	(29)		(11)
Total other income, net	954		992
Loss before income taxes	(13,319)		(13,880)
Income tax expense	3		7
Net loss	$	(13,322)	$	(13,887)
Net loss per share — basic and diluted	$	(0.31)	$	(0.32)
Weighted average common shares outstanding — basic and diluted	43,245,835		42,812,580

RAPID MICRO BIOSYSTEMS, INC.

Unaudited Condensed Consolidated Balance Sheets

(in thousands)


	March 31, 2024		December 31, 2023
Assets
Current assets:
Cash and cash equivalents	$	22,433	$	24,285
Short-term investments	57,103		67,768
Accounts receivable	4,921		5,532
Inventory	20,418		19,961
Prepaid expenses and other current assets	3,285		2,869
Total current assets	108,160		120,415
Property and equipment, net	12,615		12,832
Right-of-use assets, net	5,988		6,240
Long-term investments	—		2,911
Other long-term assets	684		770
Restricted cash	284		284
Total assets	$	127,731	$	143,452
Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,164	$	1,973
Accrued expenses and other current liabilities	7,049		9,907
Deferred revenue	6,234		5,974
Lease liabilities, short-term	1,153		1,132
Total current liabilities	15,600		18,986

Lease liabilities, long-term	5,916		6,214
Other long-term liabilities	272		263
Total liabilities	21,788		25,463
Total stockholders’ equity	105,943		117,989
Total liabilities and stockholders’ equity	$	127,731	$	143,452

RAPID MICRO BIOSYSTEMS, INC.

Unaudited Cash, Cash Equivalents and Investments

(in thousands)


	March 31, 2024		December 31, 2023
Cash and cash equivalents	$	22,433	$	24,285
Short-term investments	57,103		67,768
Long-term investments	—		2,911
Cash, cash equivalents and investments	$	79,536	$	94,964

EX-101.SCH 3 rpid-20240503.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 rpid-20240503_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Address, Address Line Two Entity Address, Address Line Two Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Entity Ex Transition Period Entity Ex Transition Period Amendment Flag Amendment Flag Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 rpid-20240503_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover Page	Jan. 10, 2024
Cover [Abstract]
Document Type	8-K
Document Period End Date	May 03, 2024
Entity Registrant Name	RAPID MICRO BIOSYSTEMS, INC.
Entity Incorporation, State or Country Code	DE
Entity File Number	001-40592
Entity Tax Identification Number	20-8121647
Entity Address, Address Line One	1001 Pawtucket Boulevard West
Entity Address, Address Line Two	Suite 280
Entity Address, City or Town	Lowell,
Entity Address, State or Province	MA
Entity Address, Postal Zip Code	01854
City Area Code	978
Local Phone Number	349-3200
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Class A Common Stock, $0.01 par value per share
Trading Symbol	RPID
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Central Index Key	0001380106
Amendment Flag	false

EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.1.u1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Sheet http://rapidmicrobio.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports rpid-20240503.htm rpid-20240503.xsd rpid-20240503_lab.xml rpid-20240503_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "rpid-20240503.htm": { "nsprefix": "rpid", "nsuri": "http://rapidmicrobio.com/20240503", "dts": { "inline": { "local": [ "rpid-20240503.htm" ] }, "schema": { "local": [ "rpid-20240503.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] }, "labelLink": { "local": [ "rpid-20240503_lab.xml" ] }, "presentationLink": { "local": [ "rpid-20240503_pre.xml" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2022": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 25, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "report": { "R1": { "role": "http://rapidmicrobio.com/role/CoverPage", "longName": "0000001 - Document - Cover Page", "shortName": "Cover Page", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rpid-20240503.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "c-1", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "div", "body", "html" ], "reportCount": 1, "baseRef": "rpid-20240503.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "AmendmentFlag", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Amendment Flag", "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CityAreaCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "City Area Code", "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "terseLabel": "Cover [Abstract]", "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentPeriodEndDate", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Period End Date", "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "DocumentType", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Document Type", "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine1", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line One", "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressAddressLine2", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Address Line Two", "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressCityOrTown", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, City or Town", "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, Postal Zip Code", "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Address, State or Province", "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityCentralIndexKey", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Central Index Key", "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Emerging Growth Company", "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityExTransitionPeriod", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Ex Transition Period", "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r7" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityFileNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity File Number", "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Incorporation, State or Country Code", "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityRegistrantName", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Registrant Name", "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Entity Tax Identification Number", "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "LocalPhoneNumber", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Local Phone Number", "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Issuer Tender Offer", "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "PreCommencementTenderOffer", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Pre-commencement Tender Offer", "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "Security12bTitle", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Title of 12(b) Security", "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SecurityExchangeName", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Security Exchange Name", "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r2" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "SolicitingMaterial", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Soliciting Material", "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r5" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "TradingSymbol", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Trading Symbol", "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2022", "localname": "WrittenCommunications", "presentation": [ "http://rapidmicrobio.com/role/CoverPage" ], "lang": { "en-us": { "role": { "terseLabel": "Written Communications", "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r6" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001380106-24-000125-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001380106-24-000125-xbrl.zip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end XML 17 rpid-20240503_htm.xml IDEA: XBRL DOCUMENT 0001380106 2024-01-10 2024-01-10 0001380106 false 8-K 2024-05-03 RAPID MICRO BIOSYSTEMS, INC. DE 001-40592 20-8121647 1001 Pawtucket Boulevard West Suite 280 Lowell, MA 01854 978 349-3200 false false false false Class A Common Stock, $0.01 par value per share RPID NASDAQ true false